ConductScience.org, home

Paper36239658

Pembrolizumab in Triple-Negative Breast Cancer. Reply.

Cortes J and 2 others. N Engl J Med, 2022. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Pembrolizumab in Triple-Negative Breast Cancer. Reply. Papers, record 36239658. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36239658

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pembrolizumab in Triple-Negative Breast Cancer. Reply.
PubMed
Journal
N Engl J Med
PubMed
Year
2022
PubMed
Publication types
Letter, Comment
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.27
iCite
Revised in PubMed
2022-10-21
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cortes JJavier
2Zhou XXuan
3Schmid PPeter

Source PubMed

Download CSV of authors

Topics3

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Triple Negative Breast NeoplasmsMajor topic
Antibodies, Monoclonal, Humanized
Humans

Comments and corrections2

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment on36239656Pembrolizumab in Triple-Negative Breast Cancer.https://conductscience.org/library/papers/36239656PubMed
Comment on36239657Pembrolizumab in Triple-Negative Breast Cancer.https://conductscience.org/library/papers/36239657PubMed

Download CSV of comments and corrections

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
39225730The use of nanomaterials as drug delivery systems and anticancer agents in the treatment of triple-negative breast cancer: an updated review (year 2005 to date).Discov Nano2024https://conductscience.org/library/papers/39225730PubMed
38336982Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.Clin Transl Oncol2024https://conductscience.org/library/papers/38336982PubMed
37873189ARF6-dependent endocytic trafficking of the Interferon-γ receptor drives adaptive immune resistance in cancer.bioRxiv2023https://conductscience.org/library/papers/37873189PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36239658

GET https://conductscience.org/api/papers/v1/36239658/authors